<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TAPAZOLE - methimazole tablet </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>Tapazole® Methimazole Tablets, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<a href="http://"></a><p class="First"></p>
<p>TAPAZOLE<span class="Sup">®</span> (Methimazole Tablets, USP) (1-methylimidazole-2-thiol) is a white, crystalline substance that is freely soluble in water. It differs chemically from the drugs of the thiouracil series primarily because it has a 5- instead of a 6-membered ring.</p>
<p>Each tablet contains 5 or 10 mg (43.8 or 87.6 µmol) methimazole, an orally administered antithyroid drug.</p>
<p>Each tablet also contains lactose monohydrate, magnesium stearate, starch (corn), pregelatinized starch and talc.</p>
<p>The molecular weight is 114.16, and the molecular formula is C<span class="Sub">4</span>H<span class="Sub">6</span>N<span class="Sub">2</span>S. The structural formula is as follows:</p>
<div class="Figure"><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0659f574-542f-4931-8fe7-d9f6b431bb9a&amp;name=MM1.jpg"></div>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<a href="http://"></a><p class="First"></p>
<p>Methimazole inhibits the synthesis of thyroid hormones and thus is effective in the treatment of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. The drug does not inactivate existing thyroxine and tri-iodothyronine that are stored in the thyroid or circulating in the blood nor does it interfere with the effectiveness of thyroid hormones given by mouth or by injection.</p>
<p>Methimazole is readily absorbed in the gastrointestinal tract, metabolized in the liver, and excreted in the urine.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<a href="http://"></a><p class="First"></p>
<p>TAPAZOLE is indicated:</p>
<ul>
<li>In patients with Graves' disease with <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> or   toxic multinodular <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> for whom surgery or radioactive iodine therapy   is not an appropriate treatment option.</li>
<li>To ameliorate symptoms of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> in preparation   for thyroidectomy or radioactive iodine therapy.</li>
</ul>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>TAPAZOLE is contraindicated in the presence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or any of the other product components.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<a href="http://"></a><p class="First"></p>
<p>Methimazole readily crosses the placental membranes and can cause fetal harm, particularly when administered in the first trimester of pregnancy. Rare instances of congenital defects, including <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span> cutis, craniofacial malformations (<span class="product-label-link" type="condition" conceptid="439394" conceptname="Congenital anomaly of face">facial dysmorphism</span>; <span class="product-label-link" type="condition" conceptid="256810" conceptname="Choanal atresia">choanal atresia</span>) and gastrointestinal malformations (<span class="product-label-link" type="condition" conceptid="4095108" conceptname="Congenital atresia of esophagus">esophageal atresia</span> with or without <span class="product-label-link" type="condition" conceptid="25582" conceptname="Tracheoesophageal fistula">tracheoesophageal fistula</span>; umbilical abnormalities) have occurred in infants born to mothers who received TAPAZOLE during pregnancy. If TAPAZOLE is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be warned of the potential hazard to the fetus.</p>
<p>Since the above congenital defects have been reported in offspring of patients treated with TAPAZOLE, it may be appropriate to use other agents in pregnant women requiring treatment for <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, particularly during organogenesis, in the first trimester of pregnancy. If TAPAZOLE is used, the lowest possible dose to control the maternal disease should be given.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> is potentially a life-threatening adverse reaction of TAPAZOLE therapy. Patients should be instructed to immediately report to their physicians any symptoms suggestive of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> (<span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>) may also occur. The drug should be discontinued in the presence of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> (<span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>), <span class="product-label-link" type="condition" conceptid="4012393" conceptname="Antiproteinase 3 antibody">ANCA</span>-positive <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, or <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> and the patient's bone marrow indices should be monitored.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Although there have been reports of hepatotoxicity (including <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>) associated with TAPAZOLE, the risk of hepatotoxicity appears to be less with methimazole than with propylthiouracil, especially in the pediatric population. Symptoms suggestive of hepatic dysfunction (<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, pruritis, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">right upper quadrant pain</span>, etc.) should prompt evaluation of liver function (bilirubin, alkaline phosphatase) and hepatocellur integrity (ALT, AST). Drug treatment should be discontinued promptly in the event of clinically significant evidence of liver abnormality including hepatic transaminase values exceeding 3 times the upper limit of normal.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>TAPAZOLE can cause <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> necessitating routine monitoring of TSH and free T4 levels with adjustments in dosing to maintain a euthyroid state. Because the drug readily crosses placental membranes, methimazole can cause fetal <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> and <span class="product-label-link" type="condition" conceptid="133728" conceptname="Congenital hypothyroidism">cretinism</span> when administered to a pregnant woman. For this reason, it is important that a sufficient, but not excessive, dose be given during pregnancy (see <a href="#Pregnancy">PRECAUTIONS, Pregnancy</a>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>Patients who receive methimazole should be under close surveillance and should be cautioned to report immediately any evidence of illness, particularly <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, or <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. In such cases, white-blood-cell and differential counts should be obtained to determine whether <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> has developed. Particular care should be exercised with patients who are receiving additional drugs known to cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Because methimazole may cause <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be monitored during therapy with the drug, especially before surgical procedures. <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">Thyroid function tests</span> should be monitored periodically during therapy. Once clinical evidence of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> has resolved, the finding of a rising serum TSH indicates that a lower maintenance dose of TAPAZOLE should be employed.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span> may cause an increased clearance of beta blockers with a high extraction ratio. A dose reduction of beta-adrenergic blockers may be needed when a hyperthyroid patient becomes euthyroid.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; a reduced dosage of digitalis glycosides may be needed.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>In a 2 year study, rats were given methimazole at doses of 0.5, 3, and 18 mg/kg/day. These doses were 0.3, 2, and 12 times the 15 mg/day maximum human maintenance dose (when calculated on the basis of surface area). <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">Thyroid hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenoma</span>, and carcinoma developed in rats at the two higher doses. The clinical significance of these findings is unclear.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Due to the rare occurrence of congenital malformations associated with methimazole use, it may be appropriate to use other agents in pregnant women requiring treatment for <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> particularly in the first trimester of pregnancy (during organogenesis).</p>
<p>Patients should be advised that if they become pregnant or intend to become pregnant while taking an antithyoid drug, they should contact their physician immediately about their therapy.</p>
<p>In many pregnant women, the thyroid dysfunction diminishes as the pregnancy proceeds; consequently, a reduction in dosage of anti-thyroid therapy may be possible. In some instances, use of anti-thyroid therapy can be discontinues 2 or 3 weeks before delivery. Because the drug readily crosses placental membranes, methimazole can cause fetal <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span> and <span class="product-label-link" type="condition" conceptid="133728" conceptname="Congenital hypothyroidism">cretinism</span> when administered to a pregnant woman. For this reason, it is important that a sufficient, but not excessive, dose be given during pregnancy (see <a href="#WARNINGS">WARNINGS</a>).</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Methimazole is excreted into breast milk. However, several studies found no effect on clinical status in nursing infants of mothers taking methimazole, particularly if thyroid function is monitored at frequent (weekly or biweekly) intervals. A long-term study of 139 thyrotoxic lactating mothers and their infants failed to demonstrate toxicity in infants who are nursed by mothers receiving treatment with methimazole.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Because of postmarketing reports of severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> in pediatric patient treated with propylthiouracil, TAPAZOLE is the preferred choice when an antithyroid drug is required for a pediatric patient (see <a href="#DA">DOSAGE AND ADMINISTRATION</a>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<a href="http://"></a><p class="First"></p>
<p>Major adverse reactions (which occur with much less frequency than the minor adverse reactions) include inhibition of myelopoieses (<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, a lupus-like syndrome, <span class="product-label-link" type="condition" conceptid="4252384" conceptname="Insulin autoimmune syndrome">insulin autoimmune syndrome</span> (which can result in <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span>), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> may persist for several weeks after discontinuation of the drug), periarteritis, and <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>. <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">Nephritis</span> occurs very rarely.</p>
<p>Minor adverse reactions include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span>, abnormal loss of hair, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">skin pigmentation</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, sialadenopathy, and <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<a href="http://"></a><p class="First"></p>
<p>Symptoms may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span> (<span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>) or <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> may be manifested in hours to days. Less frequent events are <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, neuropathies, and CNS stimulation or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. No information is available on the median lethal dose of the drug or the concentration of methimazole in biologic fluids associated with toxicity and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison Control Center. In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics in the patient.</p>
<p>In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, appropriate supportive treatment should be initiated as dictated by the patient's medical status.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<a href="http://"></a><p class="First"></p>
<p>TAPAZOLE is administered orally. The total daily dosage is usually given in 3 divided doses at approximately 8-hour intervals.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>The initial daily dosage is 15 mg for mild <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, 30 to 40 mg for moderately severe <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, and 60 mg for severe <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, divided into 3 doses at 8-hour intervals. The maintenance dosage is 5 to 15 mg daily.</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Initially, the daily dosage is 0.4 mg/kg of body weight divided into 3 doses and given at 8-hour intervals. The maintenance dosage is approximately 1/2 of the initial dose.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<a href="http://"></a><p class="First"></p>
<p>TAPAZOLE Tablets are available in:</p>
<p>The 5-mg tablets are round, white to off-white, scored on one side and the other side debossed with "J94".</p>
<p>They are available as follows:</p>
<p>Bottles of 100 <span class="Bold">NDC</span> 60793-104-01</p>
<p>The 10-mg tablets are round, white to off-white, scored on one side and the other side debossed with "J95".</p>
<p>They are available as follows:</p>
<p>Bottles of 100 <span class="Bold">NDC</span> 60793-105-01</p>
<p>
 
</p>
<a href="http://"></a><p></p>
<p>Store at controlled room temperature, 15° to 30°C (59° to 86°F).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<a href="http://"></a><p class="First"></p>
<p>Distributed by: King Pharmaceuticals, Inc. Bristol, TN 37620<br>Manufactured by: AAI Pharma, 1726 North 23rd St., Wilmington, NC 28405</p>
<p>LAB-0602-1.0</p>
<p>February 2012</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
    DRUG: TAPAZOLE <br>GENERIC: methimazole<br>DOSAGE: TABLET<br>ADMINSTRATION: ORAL<br>NDC: 52125-133-02<br>STRENGTH:10 mg<br>COLOR: white<br>SHAPE: ROUND<br>SCORE: Two even pieces<br>SIZE: 8 mm<br>IMPRINT: 30<br>QTY: 30<br><br><div class="Figure"><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0659f574-542f-4931-8fe7-d9f6b431bb9a&amp;name=MM2.jpg"></div>
<div class="Figure"><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0659f574-542f-4931-8fe7-d9f6b431bb9a&amp;name=MM3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TAPAZOLE 		
					</strong><br><span class="contentTableReg">methimazole tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-133(NDC:60793-105)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHIMAZOLE</strong> (METHIMAZOLE) </td>
<td class="formItem">METHIMAZOLE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (TABLET) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">J95</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-133-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040320</td>
<td class="formItem">03/13/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3682b0e1-c5db-49d7-ab75-262dd87b1518</div>
<div>Set id: 0659f574-542f-4931-8fe7-d9f6b431bb9a</div>
<div>Version: 1</div>
<div>Effective Time: 20130313</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
